YD Bio Ltd. is a biotechnology company building an integrated healthcare platform across regulated diagnostics, clinical services, and commercial healthcare markets. The company is headquartered in Taipei City, Taipei. The company went IPO on 2025-08-29. The firm is focused on blood-based cancer detection, the development of stem cell- and exosome-based therapeutics with the potential to transform the treatment of diseases with unmet medical need and serving as a trusted supplier of clinical testing drugs for pharmaceutical companies. The company is focused on advancing a diversified portfolio of healthcare solutions across oncology diagnostics, regenerative medicine and clinical trial support. The company is a supplier of clinical trial drugs and has expanded into the development and distribution of post-market auxiliary products. Its core programs include Blood-Based Cancer Detection, Stem Cell- and Exosome-Based Ophthalmology Therapies, and Clinical Trial and AncillaryServices. The company is developing proprietary DNA methylation-based detection technology for a range of cancers, which includes a screening test for the early detection of pancreatic cancer and a monitoring test for recurrent breast cancer.
YDES'ün son EPS'si beklentilerle karşılaştırıldığında nasıldı?
YD Bio Ltd'in en son EPS'si $ olup, $ beklentilerini .
YD Bio Ltd YDES'ün son çeyrekteki geliri nasıl performans gösterdi?
YD Bio Ltd'in son çeyrek geliri $
YD Bio Ltd'in gelir tahmini nedir?
Wall Street analistine göre, YD Bio Ltd'in gelir tahmini $ ile $ arasında değişmektedir.
YD Bio Ltd'in kazanç kalite puanı nedir?
YD Bio Ltd'in kazanç kalite puanı B+/52.34472'dir. Puan, karlılık, büyüme, nakit üretimi ve sermaye tahsisi ile kaldıraç olmak üzere dört boyuta dayanır.
YD Bio Ltd kazançlarını ne zaman rapor eder?
YD Bio Ltd'in bir sonraki kazanç raporu 2026-07-29'te bekleniyor
YD Bio Ltd'in beklenen kazançları nelerdir?
Wall Street analistlerine göre YD Bio Ltd'in beklenen kazançları $'dir.
YD Bio Ltd kazanç beklentilerini aştı mı?
YD Bio Ltd'in son kazançları $ olup, beklentileri .